Back to Browse Journals » Journal of Inflammation Research » Volume 3

Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis

Authors Slobodan M Jankovic

Published 16 March 2010 Volume 2010:3 Pages 25—31


Review by Single-blind

Peer reviewer comments 5

Slobodan M Jankovic

Pharmacology Department, Medical Faculty, University of Kragujevac, Kragujevac, Serbia

Abstract: Multiple sclerosis (MS) is chronic inflammatory and demyelinating disease with either a progressive (10%–15%) or relapsing-remitting (85%–90%) course. The pathological hallmarks of MS are lesions of both white and grey matter in the central nervous system. The onset of the disease is usually around 30 years of age. The patients experience an acute focal neurologic dysfunction which is not characteristic, followed by partial or complete recovery. Acute episodes of neurologic dysfunction with diverse signs and symptoms will then recur throughout the life of a patient, with periods of partial or complete remission and clinical stability in between. Currently, there are several therapeutic options for MS with disease-modifying properties. Immunomodulatory therapy with interferon beta-1b (IFN-β1b) or -1a, glatiramer and natalizumab shows similar efficacy; in a resistant or intolerant patient, the most recently approved therapeutic option is mitoxantrone. IFN-β1b in patients with MS binds to specific receptors on surface of immune cells, changing the expression of several genes and leading to a decrease in quantity of cell-associated adhesion molecules, inhibition of major histocompatibility complex class II expression and reduction in inflammatory cells migration into the central nervous system. After 2 years of treatment, IFN-β1b reduces the risk of development of clinically defined MS from 45% (with placebo) to 28% (with IFN-β1b). It also reduces relapses for 34% (1.31 exacerbations annually with placebo and 0.9 with higher dose of IFN-β1b) and makes 31% more patients relapse-free. In secondary-progressive disease annual rate of progression is 3% lower with IFN-β1b. In recommended doses IFN-β1b causes the following frequent adverse effects: injection site reactions (redness, discoloration, inflammation, pain, necrosis and non-specific reactions), insomnia, influenza-like syndrome, asthenia, headache, myalgia, hypoesthesia, nausea, paresthesia, myasthenia, chills and depression. Efficacy of IFN-β1b in  relapsing-remitting MS is higher than that of IFN-β1a, and similar to the efficacy of glatiramer acetate. These facts promote IFN-β1b as one of the most important drugs in the spectrum of immunological therapies for this debilitating disease.
Keywords: multiple sclerosis, interferon beta 1b, mechanism of action, efficacy, safety

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries

Cimino E, Linari S, Malerba M, Halimeh S, Biondo F, Westfeld M

Patient Preference and Adherence 2014, 8:1713-1720

Published Date: 12 December 2014


Cárdenas WH, Mamani JB, Sibov TT, Caous CA, Amaro E Jr, Gamarra LF

International Journal of Nanomedicine 2012, 7:5107-5108

Published Date: 21 September 2012

Exacerbation frequency and course of COPD

Halpin DMG, Decramer M, Celli B, Kesten S, Liu D, Tashkin DP

International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:653-661

Published Date: 21 September 2012

The effects of lean beef supplementation on the iron status of college athletes

Johnson J, Burke D, Vukovich M, Kattelmann K

Nutrition and Dietary Supplements 2012, 4:39-45

Published Date: 12 July 2012

Effects of a cellulose mask synthesized by a bacterium on facial skin characteristics and user satisfaction

Amnuaikit T, Chusuit T, Raknam P, Boonme P

Medical Devices: Evidence and Research 2011, 4:77-81

Published Date: 23 June 2011

Small bowel intussusception due to metastatic intestinal carcinosarcoma from a pulmonary primary

Ya-Fen Hsu, Chi-Yu Huang, Tong-Jong Chen, et al

International Medical Case Reports Journal 2011, 4:1-5

Published Date: 16 December 2010

Success rates in the correction of astigmatism with toric and spherical soft contact lens fittings

Sevda Aydin Kurna, Tomris Şengör, Murat Ün, et al

Clinical Ophthalmology 2010, 4:959-966

Published Date: 20 August 2010

Agomelatine: The evidence for its place in the treatment of depression

Daniela Eser, Thomas C Baghai, Hans-Jürgen Möller

Core Evidence 2009, 4:171-179

Published Date: 5 August 2009

Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase)

Andrea Pession, Fraia Melchionda, Claudia Castellini

Biologics: Targets and Therapy 2008, 2:129-141

Published Date: 7 March 2008